María del Rosario
García Campelo
Publicacións (123) Publicacións de María del Rosario García Campelo
2024
-
Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients
Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 88-94
-
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry
Lung Cancer, Vol. 190
-
Difficulties on the access to innovative targeted therapies for lung cancer in Spain
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612
-
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Clinical and Translational Oncology
-
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 12, pp. 1350-1356
-
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76
2023
-
Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study
ERJ Open Research, Vol. 9, Núm. 6
-
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer
Clinical Lung Cancer
-
Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)
Scientific Reports
-
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer
Expert Review of Anticancer Therapy, Vol. 23, Núm. 1, pp. 95-106
-
Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2679-2691), 10.1007/s12094-023-03216-3)
Clinical and Translational Oncology
-
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations
Journal of Thoracic Oncology, Vol. 18, Núm. 11, pp. 1581-1593
-
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Nature Reviews Clinical Oncology, Vol. 20, Núm. 10, pp. 664-677
-
MET alterations in NSCLC—Current Perspectives and Future Challenges
Journal of Thoracic Oncology, Vol. 18, Núm. 4, pp. 419-435
-
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
Journal of Clinical Medicine, Vol. 12, Núm. 1
-
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry
JTO Clinical and Research Reports, Vol. 4, Núm. 1
-
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Annals of Oncology, Vol. 34, Núm. 5, pp. 468-476
-
Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial
Lung Cancer, Vol. 185
-
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
Annals of Oncology, Vol. 34, Núm. 10, pp. 920-933
-
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2679-2691